It's very hard to grab market share from the incumbents, the company is growing but not fast enough or as fast we share holders have expected, I think the situation with the TAVR will be different than our patch business in the sense that they will have a much harder wearing heart valve and thinner made from superior tissue.
Also being made from one piece will give the company a price advantage on our competition, where as in the patch market they are trying to sell the patch products at a premium which made the task even harder.
Response from AHZ, page-28
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |